Showing results (231-240 of 331) with videos related to
Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK InhibitionRebecca L Shattuck-Brandt, Sheau-Chiann Chen, Emily Murray, et al.JAAD International|March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyXue Bai, Aleigha R Lawless, Juliane A Czapla, et al.Journal for Immunotherapy of Cancer|January 31, 2024
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case seriesCatriona Harvey, Kazi J Nahar, Janet McKeown, et al.European Journal of Cancer (Oxford, England : 1990)|December 12, 2022
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomesJoanna Lee, Tasnia Ahmed, Andrea Maurichi, et al.European Journal of Cancer (Oxford, England : 1990)|October 12, 2023
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanomaRachel S Goodman, Lorenza Di Guardo, Andrea Maurichi, et al.Cancer|August 18, 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanomaAlexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, et al.The Oncologist|May 7, 2014
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panelDouglas B Johnson, Kimberly H Dahlman, Jared Knol, et al.European Journal of Cancer (Oxford, England : 1990)|October 10, 2022
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective studyPatricio Serra-Bellver, Judith M Versluis, Honey K Oberoi, et al.Nature Communications|January 30, 2016
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyDouglas B Johnson, Monica V Estrada, Roberto Salgado, et al.Bioinformatics (Oxford, England)|December 6, 2022
Interactive network-based clustering and investigation of multimorbidity association matrices with associationSubgraphsNick Strayer, Siwei Zhang, Lydia Yao, et al.Pageof 34